TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04583696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The Investigation of effect on Blood Lipid parameters with walnut addition of Diet
Description: Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
Study: NCT00766831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
Study: NCT00251433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib, docetaxel, trastuzumab
Description: The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
Study: NCT03060837

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Parameters
Description: Preoperative Hmg and serum creatinine levels

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Parameters
Description: Preoperative Hmg and serum creatinine levels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroperative Parameters
Description: Scope duration, perforation, hemorrhage, etc. complications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peroperative Parameters
Description: Scope duration, perforation, hemorrhage, etc. complications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Parameters
Description: Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
Study: NCT03702673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 CR Tablet E
Description: K-877 Controlled Release Tablet E
Study: NCT04217655

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography
Description: Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose computed tomography
Description: Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
Study: NCT00396461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCT/LCT (1:1)
Description: Emulsion based on 20% MCT/LCT (50:50 ratio)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT/LCT/omega-3 (5:4:1)
Description: Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
Study: NCT02212340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fresofol and remifentanil
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane and remifentanil
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Study: NCT00850226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT
Description: Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
Study: NCT01813071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WRSS1
Study: NCT01120769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT01158352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation formula
Description: Nutritional supplementation formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
Study: NCT04815252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIME
Description: CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
Study: NCT01267006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
Study: NCT00183586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family therapy (FT)
Description: FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy (IT)
Description: IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
Study: NCT04115709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Caresystem device with advice
Description: Beacon Caresystem device provides ventilator settings advice to Doctors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beacon Caresystem device without advice activated
Description: Beacon Caresystem device does not give ventilator settings advice
Study: NCT03351231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986242
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986242
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02240563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Study: NCT03702673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR Tablet
Description: K-877 Immediate Release Tablet
Study: NCT02240563

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non laser ordinary red light
Study: NCT03702673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR Tablet
Description: K-877 Immediate Release Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR Tablet
Description: K-877 Immediate Release Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 IR Tablet
Description: K-877 Immediate Release Tablet
Study: NCT00494780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
Study: NCT01884688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENK Cell Infusion
Description: Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
Study: NCT03116061

Intervention type: OTHER
Intervention: Questionnaire
Description: This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
Study: NCT04727684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
Study: NCT01931228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MI-E plus manually assisted coughing
Description: MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manually assisted coughing
Description: Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
Study: NCT02327507

Intervention type: BEHAVIORAL
Intervention: Toothpaste & Telephone Support
Description: Mailed toothpaste, messages and telephone support.
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.
Study: NCT02597582

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neck dissection
Description: The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck dissection
Description: The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
Study: NCT04130178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: block of the digital nerves in rheumatoid arthritis patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: subcutaneous saline injection
Study: NCT00389779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Guanfacine capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily
Study: NCT04281394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training
Description: SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional gait training
Description: even level gait training and range of motion exercises
Study: NCT03138902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TRUTOL Glucose Tolerance Beverage
Description: A caffeine-free, non-carbonated, glucose tolerance beverage
Study: NCT00253981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic Near-Infrared Light Energy (MIRE)
Description: Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Monochromatic Near-Infrared Light Energy (MIRE)
Description: Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
Study: NCT04480801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal Evaluation and Foot Care
Description: Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.

Intervention type: OTHER
Group type: OTHER
Intervention: Foot Care
Description: Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo zolpidem
Description: Placebo 3 x 10 mg zolpidem tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
Study: NCT00494780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone, Prednisone or equivalent
Description: 100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone, Prednisone or equivalent
Description: 100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
Study: NCT06110416

Intervention type: OTHER
Group type: OTHER
Intervention: nausea relief inhaler
Description: Aromatherapy and essential oils are an alternative method to controlling post-operative nausea and vomiting after post-surgical intervention.
Study: NCT03460756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03158025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo suvorexant
Description: Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
Study: NCT03503175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel urinary access system (CystoSureTM)
Description: CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Foley catheter
Description: Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
Study: NCT01122771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B
Description: Ambisome i.v. 5mg on days 1, 3 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal amphotericin B + miltefosine
Description: Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal amphotericin B + paromomycin
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine + Paromomycin
Description: Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
Study: NCT02753114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intranasal Normal Saline administered via mucosal atomization device.
Study: NCT03724032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS*
Description: Non-invasive brain stimulation (active protocol)
Study: NCT05487716

Intervention type: BEHAVIORAL
Intervention: High-intensity interval training (HIIT)
Description: Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.